Table 1.
Baseline Characteristics of Participants 1
| Standard Care N = 26 | In-person N = 26 | mHealth N = 26 | Overall p-value | |
|---|---|---|---|---|
| Male N(%) | 11 (42.3%) | 16 (61.5%) | 20 (76.9%) | 0.04 |
| Age (mean ± SD yrs) | 57.5 ± 10.9 | 58.5 ± 11.9 | 54.7 ± 11.5 | 0.47 |
| White Not-Hispanic N(%) | 24 (92.3%) | 25 (96.2%) | 25 (96.2%) | 0.77 |
| Bulbar Onset N(%) | 3 (11.5%) | 2 (7.7%) | 4 (15.4%) | 0.69 |
| ALSFRS-R (mean ± SD) | 36.7 ± 5.4 | 34.9 ± 6.7 | 37.4 ± 6.2 | 0.35 |
| Months since symptom onset (mean ± SD) | 22.3 (18.0) | 26.1 (16.8) | 27.1 (18.9) | 0.60 |
| BMI (mean ± SD kg/m2) | 26.8 ± 5.1 | 25.7 ± 4.1 | 26.0 ± 4.5 | 0.70 |
| Weight loss since diagnosis (mean ± SD kg) | 3.4 ± 5.5 | 6.3 ± 7.1 | 2.1 ± 3.4 | 0.03 |
| Weight loss since max weight (mean ± SD kg) | 7.8 ± 9.4 | 10.4 ± 10.7 | 6.0 ± 6.7 | 0.23 |
| Change in BMI since diagnosis (mean ± SD kg/m2) | 1.2 ± 1.9 | 2.2 ± 2.6 | 0.6 ± 1.0 | 0.01 |
1 Baseline characteristics of participants are shown according to treatment group in frequency (N) and percent or mean and standard deviation (SD); Bulbar onset = symptoms of ALS beginning in the cranial nerves; ALSFRS-R = ALS Functional Rating Scale-Revised; BMI = body mass index